STAAR Surgical Company STAA

STAA Company Overview

STAAR Surgical Company (NASDAQ: STAA) is a medical technology company focused on ophthalmic surgery, specializing in implantable lenses used to correct refractive vision disorders. The company operates within the global eye care and medical device industries, with its primary business centered on the development, manufacture, and commercialization of implantable Collamer® lenses (ICLs) for myopia, astigmatism, and related refractive conditions. STAAR’s core revenue driver is its EVO family of implantable lenses, which are used as an alternative to laser-based refractive procedures such as LASIK. The company primarily serves ophthalmic surgeons, refractive surgery clinics, and eye care providers across international markets.

STAAR Surgical was founded in 1982 and is headquartered in Lake Forest, California. The company evolved from a broader ophthalmic device manufacturer into a specialized refractive vision company with significant emphasis on phakic intraocular lens technology. A key differentiator is its proprietary Collamer biomaterial, designed for biocompatibility and optical performance. Over time, STAAR expanded its market presence through regulatory approvals in Europe, Asia-Pacific, and the United States, including U.S. FDA approval for the EVO Visian ICL product line. The company has established a particularly strong position in Asia, where demand for myopia correction procedures has grown substantially.